Compare DIOD & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DIOD | TLX |
|---|---|---|
| Founded | 1959 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 1995 | 2024 |
| Metric | DIOD | TLX |
|---|---|---|
| Price | $91.79 | $11.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $92.67 | $21.13 |
| AVG Volume (30 Days) | ★ 675.2K | 122.3K |
| Earning Date | 05-07-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.53 | N/A |
| EPS | ★ 1.33 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.08 | N/A |
| Revenue Next Year | $14.46 | N/A |
| P/E Ratio | ★ $67.81 | $150.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $42.28 | $6.28 |
| 52 Week High | $125.99 | $12.48 |
| Indicator | DIOD | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.05 | 55.51 |
| Support Level | $89.62 | $10.12 |
| Resistance Level | $99.29 | $12.35 |
| Average True Range (ATR) | 4.50 | 0.23 |
| MACD | -0.63 | -0.06 |
| Stochastic Oscillator | 18.15 | 56.85 |
Diodes Inc is a manufacturer and supplier of high-quality application-specific products within the broad discrete, logic, analog, and mixed-signal semiconductor markets. It serves the customer electronics, computing, communications, industrial, and automotive markets. The Company's products include diodes; rectifiers; transistors; MOSFETs; GPP bridges; GPP rectifiers; protection devices; function-specific arrays; single gate logic; amplifiers and comparators; Hall-effect and temperature sensors; and power management devices, including LED drivers, AC-DC converters and controllers, DC-DC switching and linear voltage regulators, voltage references along with special-function devices, such as USB power switches, load switches, voltage supervisors, and motor controllers.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.